Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640809 · ClinicalTrials.gov registry record · Phase 4
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 408
- Enrollment target
NCT00640809: Completed Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00640809 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 408 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640809, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 408 participants
- Enrollment target
Study Summary
To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
Interventions
- OTHER Placebo
- DRUG Celecoxib
- DRUG Ibuprofen plus Omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-04 |
| Phase | Phase 4 |
What the finished NCT00640809 record still lists
NCT00640809 is an interventional study that assigns participants to a tested intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00640809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00640809 about?
NCT00640809 is a clinical study titled "Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole". To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
What is the current status of trial NCT00640809?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 408 participants. The study started on 2003-10. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00640809?
The interventions under investigation include: Placebo (OTHER), Celecoxib (DRUG), Ibuprofen plus Omeprazole (DRUG).
Who is sponsoring clinical trial NCT00640809?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00640809's enrollment target sits among peer trials
408 208th of 2000 higher than 1,793 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia